Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Repros Therapeutics Needs New Pivotal Trial For Low T Drug Enclomiphene

This article was originally published in The Pink Sheet Daily

Executive Summary

Complete response letter from FDA follows abrupt cancellation of advisory committee meeting.


Related Content

US FDA's New Hypogonadism Guidance Focuses On Non-Testosterone Products
CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End
Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says
FDA’s Tough Stance On Patient-Reported Outcomes Underscored At Repros Meeting
Hypogonadism Trial Designs: FDA Panel Favors Symptom Assessments, Fertility Measures
FDA/Industry Dispute On Hypogonadism Drug Efficacy Endpoints To Get Panel Review


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts